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Abstract: Interleukin-7 receptor subunit alpha (IL7RA) rs6897932 polymorphism IS related to CD4+
recovery after combination antiretroviral therapy (cART), but no studies so far have analyzed its
potential impact in patients with very low CD4+ T-cells count. We aimed to analyze the association
between IL7RA rs6897932 polymorphism and CD4+ T-cells count restoration in HIV-infected
patients starting combination antiretroviral therapy (cART) with CD4+ T-cells count <200 cells/mm3.
We performed a retrospective study in 411 patients followed for 24 months with a DNA sample
available for genotyping. The change in CD4+ T-cells count during the follow-up was considered as
the primary outcome. The rs6897932 polymorphism had a minimum allele frequency (MAF) >20% and
was in Hardy–Weinberg equilibrium (p = 0.550). Of 411 patients, 256 carried the CC genotype, while
155 had the CT/TT genotype. The CT/TT genotype was associated with a higher slope of CD4+ T-cells
recovery (arithmetic mean ratio; AMR = 1.16; p = 0.016), higher CD4+ T-cells increase (AMR = 1.19;
p = 0.004), and higher CD4+ T-cells count at the end of follow-up (AMR = 1.13; p = 0.006). Besides,
rs6897932 CT/TT was related to a higher odds of having a value of CD4+ T-cells at the end of follow-up
≥500 CD4+ cells/mm3 (OR = 2.44; p = 0.006). After multiple testing correction (Benjamini–Hochberg),
only the increase of ≥ 400 CD4+ cells/mm3 lost statistical significance (p = 0.052). IL7RA rs6897932
CT/TT genotype was related to a better CD4+ T-cells recovery and it could be used to improve the
management of HIV-infected patients starting cART with CD4+ T-cells count <200 cells/mm3.
Biomolecules 2019, 9, 233; doi:10.3390/biom9060233 www.mdpi.com/journal/biomolecules
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1. Background
The majority of HIV-infected individuals on combination antiretroviral therapy (cART) achieve
undetectable levels of plasma HIV-RNA, recover CD4+ T-cell levels in peripheral blood, and restore
many immunological functions [1,2]. However, a significant number of cART-treated patients fail to
achieve substantial increases in the CD4+ T-cell count, remaining at risk of progression to acquired
immune deficiency syndrome (AIDS), non-AIDS morbidities, and death [3–5].
The underlying mechanisms to this phenomenon are complex and likely multifactorial, including
clinical features, such as age [6], hepatitis coinfection [7], severe immunodeficiency at the time of cART
initiation [8], or a low CD4+ T-cells nadir [9]. Among the immunological factors associated with a poor
restoration of CD4+ T-cells, chronic immune activation [10], levels of T-cell apoptosis [8], and reduced
thymic output [11] have already been described.
Furthermore, genetic factors have been related to CD4 T-cell restoration after virological
suppression, among them specific mitochondrial haplogroups [12] and polymorphisms in genes
encoding cytokines or cytokine receptors [13–15]. Taken together, all these factors could potentially
be employed to predict impaired CD4 T-cell recovery and avoid clinical complications. Interleukin-7
(IL-7) and IL-7 receptor (IL-7R) are essential factors for T cell homeostasis by promoting development,
survival, proliferation, and de novo production of T and B lymphocytes [16]. Besides, IL-7 has been
described as a critical factor for CD4+ T-cells recovery in HIV-infected patients on cART [17]. IL-7R is a
heterodimer formed by the common cytokine receptor γ-chain (CD132) and the α-chain specific of the
IL-7 receptor (IL7Rα or CD127) [16]. Polymorphisms in IL7RA, the gene encoding for IL7Rα, have
previously been associated with rapid progression to AIDS [18] and with CD4+ T-cell recovery after
initiation of cART, especially the missense polymorphism rs6897932 [19–22]. The IL7RA rs6897932
Single Nucleotide Polymorphism (SNP) is a missense variant located at the IL7RA gene, within the
alternatively spliced exon 6. This change (C/T) causes a substitution of threonine with isoleucine
(Ile244) in the transmembrane region of the protein [23]. The C allele is related to alternative splicing of
IL7RA that promotes an increase of the ratio between soluble IL7RA (sIL-7Rα) and membrane-bound
IL-7RA (mIL-7Rα) [21,23,24]. However, no studies so far have analyzed the potential impact of this
polymorphism on CD4+ T-cell restoration in a particular population of patients starting cART with
very low CD4+ T-cell counts, a population of patients that is growing due to late HIV diagnosis [9] and
in whom the prevalence of impaired CD4 restoration is very high [8].
2. Objective
We aimed to analyze the association between IL7RA rs6897932 SNP and CD4+ T-cell count gain in
naïve patients infected with HIV who started cART with very low CD4+ T-cell counts (<200 cells/mm3).
3. Methods
3.1. Study Population
We performed a retrospective study in 411 HIV-infected patients starting cART included in two
different cohorts: The majority of patients came from the Spanish AIDS Research Network cohort
(CoRIS); the rest of the patients came from the AIDS Research Institute IrsiCaixa-HIVACAT, Institut
de Recerca en Ciències de la Salut Germans Trias i Pujol (Barcelona, Spain) cohort. All subjects
provided informed consent to participate in the study, and the study protocol was approved by the
Fundación Jiménez Díaz Ethics Committee in concordance with the Declaration of Helsinki (approval
date: 26 May 2015; record number: PIC 52/2015_FJD). The inclusion criteria were: (i) Naïve for cART at
inclusion in the cohort; (ii) plasma HIV-RNA > 200 copies/mL; (iii) starting cART with CD4+ T-cells
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count < 200 cells/mm3; (iv) complete viral suppression (plasma HIV-RNA < 50 copies/mL) for two
years after starting cART; (v) regular follow up of CD4+ T-cells count and plasma HIV-RNA for two
years after starting cART; and (vi) DNA sample available for genotyping (Figure 1). From a total of
6160 HIV-infected patients included in the CoRIS and HIVACAT cohorts, 411 patients meeting all the
inclusion criteria were analyzed.
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3.2. DNA Genotyping
Samples were processed and frozen immediately after their reception in the HIV HGM BioBank
(http://hivhgmbiobank.com/?lang=en). Total DNA isolation was performed from peripheral blood
mononuclear cells with Qiagen columns (QIAamp DNA Blood Midi/Maxi; Qiagen, Hilden, Germany).
DNA samples were genotyped at the Spanish National Genotyping Center (CeGen; http://www.cegen.
org/) using the iPLEX® Gold technology and Sequenom’s MassARRAY platform (San Diego, CA, USA).
3.3. Outcome Variables
The study period was 24 months. The primary outcome was the change in values of CD4+ T-cells
during the follow-up. The outcome variables analyzed were of two types: a) Continuous: Slope of
CD4+ T-cells and change in CD4+ T-cells (∆CD4+) during follow-up; and CD4+ T-cells count at the end
of follow-up; b) dichotomous: slope of CD4+ T-cells ≥10 and ≥15 CD4+ T-cells/mm3/month; increases
of ≥200, ≥300, ≥400, and ≥500 CD4+ T-cells/mm3; and CD4+ T-cells at the end of follow-up ≥350 and
≥500 CD4+ T-cells/mm3.
3.4. Statistical Analysis
Statistical analysis was performed with Statistical Package for the Social Sciences (SPSS) software
(version 22.0, SPSS INC, Chicago, IL, USA). All tests were two-tailed with p-values < 0.05 considered
significant. Categorical data and proportions were analyzed by using a Chi-squared test or Fisher´s
exact test. Mann–Whitney U test was used to compare data between independent groups when the
variables were continuous. IL7RA rs6897932 SNP was evaluated for Hardy–Weinberg equilibrium
(HWE) by Chi-square test, considering equilibrium when p > 0.05. We used the generalized linear
model (GLM) to analyze the genetic association between IL7RA rs6897932 SNP and outcome variables.
Specifically, a GLM with a gamma distribution (log-link) was used for continuous variables, and a GLM
with a binomial distribution (logit-link) was used for dichotomous variables. These tests provide the
differences between groups, the arithmetic mean ratio (AMR), and the odds ratio (OR). The multivariate
regression tests were adjusted by the main clinical characteristics at baseline: (i) Dichotomous variables:
Gender, HIV transmission by intravenous drugs use (IDU), hepatitis C and hepatitis B coinfection,
cART regimen with protease inhibitors (PI), and Caucasian origin; (ii) continuous variables: Age,
time since HIV diagnosis, and baseline CD4+ T-cells/mm3. Additionally, p-values were corrected
for multiple testing using the false discovery rate (FDR) with Benjamini and Hochberg (q-values)
procedure to reduce the risk of spurious results.
4. Results
4.1. Characteristics of the Study Population
The baseline characteristics of patients stratified by IL7RA rs6897932 genotypes are shown in
Table 1. Of the total group of patients meeting the inclusion criteria, 256 subjects carried the CC
genotype, while 155 carried the CT/TT genotype. Patients carrying the CT/TT genotype had a higher
percentage of male (p = 0.023) and of subjects of Caucasian origin (p = 0.002) but these variables were
included in the multivariate models. No significant differences were observed between both groups of
patients for the rest of the epidemiological and clinical features analyzed.
4.2. IL7RA rs6897932 Polymorphism and CD4+ T-Cells Recovery
The rs6897932 SNP displayed <5% of missing values and was in Hardy–Weinberg equilibrium
(p = 0.550). The frequency of the C allele was 79.4% and that of the T allele was 20.6%, which were in
accordance with the NCBI SNP database (https://www.ncbi.nlm.nih.gov/snp/rs6897932). Thus, in the
general European population, the rs6897932 T allelic frequency was 27.1% in the 1000 Genomes Project
phase3 (1000Genomes) and 28.2% in the genome Aggregation Database (gnomAD-Genomes).
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Table 2 shows the association between rs6897932 SNP and CD4+ T-cell recovery (full data of GLM
models in the Supplementary file). Overall, the increases in CD4+ T-cells were higher in patients
carrying rs6897932 CT/TT genotype (CT/TT versus CC). Thereby, in the adjusted analysis, patients
carrying rs6897932 CT/TT genotype had a higher slope of CD4+ T-cells (AMR = 1.16; p = 0.016), a
higher CD4+ T-cells increase (AMR = 1.19; p = 0.004), and a higher CD4+ T-cells count at the end of
follow-up (AMR = 1.13; p = 0.006). Besides, patients carrying rs6897932 CT/TT had a higher odds of
having a slope of CD4+ T-cells ≥10 CD4+ T-cells/mm3/month (OR = 1.75; p = 0.010) and ≥15 CD4+
T-cells/mm3/month (OR = 1.94; p = 0.015); a CD4+ T-cells increase ≥200 CD4+ T-cells/mm3 (OR = 1.63;
p = 0.036), ≥300 CD4+ T-cells/mm3 (OR = 1.63; p = 0.025), ≥400 CD4+ T-cells/mm3 (OR = 1.63; p = 0.047),
and ≥500 CD4+ T-cells/mm3 (OR = 2.16; p = 0.018); and a value of CD4+ T-cells at the end of follow-up
≥500 CD4+ T-cells/mm3 (OR = 2.44; p = 0.006). These p-values were corrected for multiple testing
using the false discovery rate (FDR) with the Benjamini and Hochberg procedure, and after doing this
correction, the statistical significance was lost only for the outcome variable of CD4+ T-cells increase
≥400 CD4+ cells/mm3 (q-value = 0.052).
Table 1. Clinical and epidemiological characteristics at baseline of HIV infected patients who started
combination antiretroviral therapy with very low CD4+ T-cells count (<200 cells/mm3).
Characteristics All Patients
IL7RA rs6897932 Genotypes
CC CT/TT p-Value
No. 411 256 155
Male (n = 411) (%) 323 (78.6%) 192 (75%) 131 (84.5%) 0.023
Age (n = 411) (years) 40 (34; 48) 40 (34; 46) 50 (33; 49) 0.488
Caucasian origin (n = 394) (%) 317 (80.5%) 187 (75.7%) 130 (88.4%) 0.002
Time since HIV diagnosis (n = 411) (years) 1 (1; 1) 1 (1; 1) 1 (1; 1) 0.517
CD4+ cell count at baseline (n = 411) (cells/µL) 104 (41; 159) 92.7 (38; 157) 115 (47; 162) 0.198
Hepatitis C infection (n = 411) (%) 32 (7.8%) 23 (9%) 9 (5.8%) 0.244
Hepatitis B infection (n = 411) (%) 20 (4.9%) 14 (5.5%) 6 (3.9%) 0.466
cART regimen (n = 411) (%) 0.054
PI-based 127 (31%) 73 (28.5%) 54 (35.1%)
NNRTI-based 205 (50%) 134 (52.3%) 71 (46.1%)
PI+NNRTI-based 53 (12.9%) 38 (14.8%) 15 (9.7%)
Others 25 (6.1%) 11 (4.4%) 14 (9.1%)
HIV transmission route (n = 384) (%) 0.079
Homosexual transmission 189 (49.2%) 106 (45.1%) 83 (55.7%)
Heterosexual transmission 139 (36.2%) 95 (40.4%) 44 (29.5%)
IDU 56 (14.6%) 34 (14.5%) 22 (14.8%)
Statistical: Values were expressed as absolute number (percentage) and median (percentile 25; percentile 75).
Significant differences are shown in bold. The percentages were calculated with respect to the available values, which
are indicated in the left column in parentheses. p-values were calculated by Chi-square and Mann–Whitney tests.
Abbreviations: IDU, intravenous drug users; HIV, Human immunodeficiency virus; cART, combination antiretroviral
therapy; PI, HIV protease inhibitor; NNRTI, non-nucleoside analogue HIV reverse transcriptase inhibitor.
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Table 2. Summary of the CD4+ T-cells recovery according to IL7RA rs6897932 polymorphism in HIV-infected patients who started combination antiretroviral therapy
with very low CD4+ T-cells count (<200 cells/mm3).
Outcomes
rs6897932 Genotypes (*) Unadjusted Analysis (*) Adjusted Analysis (**)
CC (n = 256) CT/TT (n = 155) Exp(B) (95% CI) p-Value q-Value Exp(B) (95% CI) p-Value q-Value
Slope CD4+ recovery 9.1 (5.9; 12.9) 10.3 (6.1; 14.8) 1.12 (0.99; 1.28) 0.070 0.070 1.16 (1.03; 1.31) 0.016 0.028
≥10 CD4+ cells/mm3 per month 105 (41%) 82 (52.9%) 1.61 (1.08; 2.41) 0.019 0.044 1.75 (1.14; 2.69) 0.010 0.028
≥15 CD4+ cells/mm3 per month 38 (14.8%) 37 (23.9%) 1.79 (1.08; 2.88) 0.023 0.044 1.94 (1.14; 3.30) 0.015 0.028
CD4+ increase (∆CD4+) 258 (167; 381) 295 (189; 442) 1.15 (1.02; 1.31) 0.020 0.044 1.19 (1.06; 1.34) 0.004 0.022
≥200 CD4+ cells/mm3 164 (64.1%) 114 (73.5%) 1.56 (1.01; 2.42) 0.047 0.054 1.63 (1.03; 2.57) 0.036 0.044
≥300 CD4+ cells/mm3 97 (37.9%) 75 (44.8%) 1.53 (1.03; 2.30) 0.037 0.051 1.63 (1.06; 2.49) 0.025 0.034
≥400 CD4+ cells/mm3 54 (21.1%) 48 (31%) 1.67 (1.06; 2.64) 0.025 0.044 1.63 (1.01; 2.63) 0.047 0.052
≥500 CD4+ cells/mm3 24 (9.4%) 26 (16.8%) 1.94 (1.06; 3.53) 0.028 0.044 2.16 (1.14; 4.11) 0.018 0.028
CD4+ at the end of follow-up 362 (260; 463) 425 (274; 558) 1.14 (1.03; 1.25) 0.009 0.044 1.13 (1.03; 1.24) 0.006 0.022
≥350 CD4+ cells/mm3 133 (52%) 96 (61%) 1.51 (1.01; 2.26) 0.049 0.054 1.51 (0.96; 2.37) 0.077 0.077
≥500 CD4+ cells/mm3 52 (20.3%) 59 (38.1%) 2.41 (1.54; 3.76) <0.001 0.001 2.44 (1.49; 3.99) 0.006 0.022
Statistical: (*) Values were expressed as absolute number (percentage) and median (percentile 25; percentile 75). (**), p-values were calculated by univariate regression or multivariate
regression adjusted by the most important clinical and epidemiological characteristics (see statistical analysis section). p-values, raw p-values; q-values, p-values corrected for multiple
testing using the false discovery rate (FDR) with the Benjamini and Hochberg procedure. The statistically significant differences are shown in bold. Significant differences are shown in
bold. Abbreviations: Exp(B), exponentiation of the B coefficient, which was an arithmetic mean ratio (AMR) for continuous variable and an odds ratio (OR) for categorical variables; 95%CI,
95% of confidence interval; p-value, level of significance; HIV, human immunodeficiency virus; aAMR, adjusted arithmetic mean ratio; IL7RA, interleukin 7 receptor α-chain.
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5. Discussion
In this study, HIV-infected patients carrying IL7RA rs6897932 CT/TT genotype had a better
CD4+ T-cell count recovery after starting cART with <200 CD4 T-cells/mm3. This association was
found for almost all the outcome variables analyzed, both in the univariate and in the multivariate
analysis adjusted by the main baseline characteristics. It should be noted that a large number of
outcome variables, both continuous and dichotomous, were analyzed, which reflect different effects of
immune reconstitution.
Our study supports the positive impact of rs6897932 T allele on CD4+ T-cell count recovery in
cART-treated patients, in agreement with previous studies performed in cohorts of patients with
different ethnicity and different inclusion criteria [19,20,22]. The study of Guzmán-Fulgencio et al. [19]
was performed in the Spanish population, but we want to emphasize some significant differences
concerning our study. In the previous report of Guzmán-Fulgencio et al. [19], they studied a cohort of
HIV-infected patients who had baseline CD4+ T-cells values <350 cells/mm3, from a single Spanish
reference hospital, and with a non-uniform follow-up. In the current study, we analyzed a sample
more representative of the Spanish population (our cohort of patients infected with HIV came from a
large number of hospitals spread throughout Spain), we applied a more restricted inclusion criteria (all
patients included had a baseline CD4+ T-cell count <200 cells/mm3 and undetectable plasma HIV-RNA
during the whole follow-up period), and the follow-up period was the same in all patients (24 months
after starting cART). In addition, the statistical analysis applied was different in both studies. In the
report of Guzmán-Fulgencio et al. [19], a survival analysis was performed with CD4+ T-cell count
>500 cells/mm3 as the primary outcome, whereas in the present study, we evaluated the changes in the
CD4+ T-cell count during a period of 24 months and used different threshold values to evaluate the
degree of CD4+ T-cells reconstitution.
The IL7RA rs6897932 C allele has been associated to an increase of the ratio between sIL-7Rα and
mIL-7Rα [21,23,24], leading to a reduction of the bioavailability of IL-7 and limiting its effects [25].
By contrast, rs6897932 T allele has been associated with lower plasma levels of sIL-7Rα [21,23,24],
without limiting the effect of circulating IL-7 [25]. Besides, in an in vitro model, Lundtoft et al.
identified a dominant effect of the protective IL7RA haplotype tagged by rs6897932 on mIL-7Rα
expression, whereas the risk IL7RA haplotype mainly affected the sIL-7Rα [26]. In HIV-infected
patients, rs6897932 CC genotype is associated with higher plasma levels of sIL7RA [21,24], whereas
rs6897932 TT genotype is related to lower plasma levels of sIL7RA [21,24]. Since the CD4+ T-cell count
recovery is predominantly driven by increases in CD4+CD127+ T cells in HIV-infected patients on
cART [27], rs6897932 T carriers may have an advantage because the IL-7 bioavailability is increased.
Moreover, in a recent article, Hartling et al. [28] also suggested that the effect of rs6897932 is driven
by an increased response of IL-7R to IL-7 in patients with TT genotype, which is in line with a faster
CD4+ T-cell recovery in carriers of the T allele [19–21]. Thus, the TT genotype was associated with
increased signal transduction and proliferation in response to IL-7 among HIV-infected individuals [28].
As discussed above, the rs6897932 T allele, versus C allele, may confer lower sIL-7Rα levels, higher
IL-7 bioavailability, and higher capacity of CD4+ T-cell recovery, leading to a greater immune response
against HIV infection. However, in our study, we did not have any direct functional measurements of
IL7RA rs6897932 SNP to provide additional data on the potential mechanism.
Our data suggest that IL7RA rs6897932 SNP may have an impact on clinical practice in the
population of HIV-infected patients beginning cART with very low CD4+ T-cell count, a population
that is growing due to delayed HIV diagnosis [9,29] and in whom impaired CD4 restoration is
widespread [8,30]. Thus, the CT/TT genotype is related to the immunological responders (IRs) patients
that may recover CD4+ T-cell counts to optimal levels 24 months after starting cART, whereas the CC
genotype is related to the immunological non-responders (INRs) patients that present a low increase in
CD4 T-cell counts despite successful cART and viral suppression. IL7RA rs6897932 SNP may help to
identify those patients who are at a higher risk of being INR in whom implementation of adjuvant
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therapies may be needed to improve immune reconstitution and to prevent disease progression
and death.
6. Study Limitations
Various limitations of our study need to be taken into account. Firstly, the retrospective design may
impose a selection bias and prevent the inclusion of other potential confounding variables. Secondly,
the limited sample size may have impaired the ability to detect less robust associations. Thirdly, this
study was mostly carried out on Caucasian subjects and our conclusions are only truly applicable to
this population.
7. Conclusions
In summary, the IL7RA rs6897932 CT/TT genotype was related to a better CD4+ T-cell count
recovery after 24 months of therapy in HIV-infected patients who started cART with a CD4+ T-cell
count <200 cells/mm3. Therefore, our findings could provide information to improve the management
of HIV-infected patients with poor prognosis of CD4+ T-cell recovery.
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Appendix A
“Centers and Investigators Involved in CoRIS”
Executive committee: Santiago Moreno, Inma Jarrín, David Dalmau, Maria Luisa Navarro, Maria
Isabel González, Jose Luis Blanco, Federico Garcia, Rafael Rubio, Jose Antonio Iribarren, Félix Gutiérrez,
Francesc Vidal, Juan Berenguer, Juan González.
Fieldwork, data management and analysis: Inma Jarrín, Belén Alejos, Victoria Hernando, Cristina
Moreno, Carlos Iniesta, Luis Miguel Garcia Sousa, Nieves Sanz Perez.
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HIV BioBanK: Hospital General Universitario Gregorio Marañón: M Ángeles Muñoz-Fernández,
Isabel María García-Merino, Irene Consuegra Fernández, Coral Gómez Rico, Jorge Gallego de la Fuente,
Paula Palau Concejo.
Participating centres:
Hospital General Universitario de Alicante (Alicante): Joaquín Portilla, Esperanza Merino,
Sergio Reus, Vicente Boix, Livia Giner, Carmen Gadea, Irene Portilla, María Pampliega, Marcos Díez,
Juan Carlos Rodríguez, José Sánchez-Payá.
Hospital Universitario de Canarias (San Cristobal de la Laguna): Juan Luis Gómez, Jehovana
Hernández, María Remedios Alemán, María del Mar Alonso, María Inmaculada Hernández, Felicitas
Díaz-Flores, Dácil García, Ricardo Pelazas, Ana López Lirola.
Hospital Universitario Central de Asturias (Oviedo): José Sanz Moreno, Alberto Arranz Caso,
Cristina Hernández Gutiérrez, María Novella Mena.
Hospital Universitario 12 de Octubre (Madrid): Rafael Rubio, Federico Pulido, Otilia Bisbal,
Asunción Hernando, Lourdes Domínguez, David Rial Crestelo, Laura Bermejo, Mireia Santacreu.
Hospital Universitario de Donostia (Donostia-San Sebastián): José Antonio Iribarren, Julio
Arrizabalaga, María José Aramburu, Xabier Camino, Francisco Rodríguez-Arrondo, Miguel Ángel
von Wichmann, Lidia Pascual Tomé, Miguel Ángel Goenaga, Mª Jesús Bustinduy, Harkaitz Azkune,
Maialen Ibarguren, Aitziber Lizardi, Xabier Kortajarena.
Hospital General Universitario De Elche (Elche): Félix Gutiérrez, Mar Masiá, Sergio Padilla,
Andrés Navarro, Fernando Montolio, Catalina Robledano, Joan Gregori Colomé, Araceli Adsuar,
Rafael Pascual, Marta Fernández, Elena García, José Alberto García, Xavier Barber.
Hospital General Universitario Gregorio Marañón (Madrid): Juan Berenguer, Juan Carlos
López Bernaldo de Quirós, Isabel Gutiérrez, Margarita Ramírez, Belén Padilla, Paloma Gijón, Teresa
Aldamiz-Echevarría, Francisco Tejerina, Francisco José Parras, Pascual Balsalobre, Cristina Diez, Leire
Pérez Latorre.
Hospital Universitari de Tarragona Joan XXIII (Tarragona): Francesc Vidal, Joaquín Peraire,
Consuelo Viladés, Sergio Veloso, Montserrat Vargas, Miguel López-Dupla, Montserrat Olona, Anna
Rull, Esther Rodríguez-Gallego, Verónica Alba.
Hospital Universitario y Politécnico de La Fe (Valencia): Marta Montero Alonso, José López
Aldeguer, Marino Blanes Juliá, María Tasias Pitarch, Iván Castro Hernández, Eva Calabuig Muñoz,
Sandra Cuéllar Tovar, Miguel Salavert Lletí, Juan Fernández Navarro.
Hospital Universitario La Paz/IdiPAZ: Juan González-garcia, Francisco Arnalich, José Ramón
Arribas, Jose Ignacio Bernardino de la Serna, Juan Miguel Castro, Luis Escosa, Pedro Herranz, Victor
Hontañón, Silvia García-Bujalance, Milagros García López-Hortelano, Alicia González-Baeza, Maria
Luz Martín-Carbonero, Mario Mayoral, Maria Jose Mellado, Rafael Esteban Micán, Rocio Montejano,
María Luisa Montes, Victoria Moreno, Ignacio Pérez-Valero, Berta Rodés, Talia Sainz, Elena Sendagorta,
Natalia Stella Alcáriz, Eulalia Valencia.
Hospital San Pedro Centro de Investigación Biomédica de La Rioja (CIBIR) (Logroño): José
Ramón Blanco, JoséAntonio Oteo, Valvanera Ibarra, Luis Metola, Mercedes Sanz, Laura Pérez-Martínez.
Hospital Universitari MutuaTerrassa (Terrasa): David Dalmau, Angels Jaén, Montse Sanmartí,
Mireia Cairó, Javier Martinez-Lacasa, Pablo Velli, Roser Font, Mariona Xercavins, Noemí Alonso.
Complejo Hospitalario de Navarra (Pamplona) María Rivero, Jesús Repáraz, María Gracia Ruiz
de Alda, María Teresa de León Cano, Beatriz Pierola Ruiz de Galarreta.
Corporació Sanitària Parc Taulí (Sabadell): Ferrán Segura, María José Amengual, Gemma
Navarro, Montserrat Sala, Manuel Cervantes, Valentín Pineda, Sonia Calzado, Marta Navarro.
Hospital Universitario de La Princesa (Madrid): Ignacio de los Santos, Jesús Sanz Sanz, Ana
Salas Aparicio, Cristina Sarriá Cepeda, Lucio Garcia-Fraile Fraile, Enrique Martín Gayo.
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Hospital Universitario Ramón y Cajal (Madrid): Santiago Moreno, José Luis Casado, Fernando
Dronda, Ana Moreno, María Jesús Pérez Elías, Cristina Gómez Ayerbe, Carolina Gutiérrez, Nadia
Madrid, Santos del Campo Terrón, Paloma Martí, Uxua Ansa, Sergio Serrano, María Jesús Vivancos.
Hospital General Universitario Reina Sofía (Murcia) Enrique Bernal, Alfredo Cano, Antonia
Alcaraz García, Joaquín Bravo Urbieta, Ángeles Muñoz, Maria Jose Alcaraz, Maria del Carmen Villalba.
Hospital Nuevo San Cecilio (Granada): Federico García, José Hernández, Alejandro Peña,
Leopoldo Muñoz, Paz Casas, Marta Alvarez, Natalia Chueca, David Vinuesa, Clara Martinez-Montes.
Centro Sanitario Sandoval (Madrid): Jorge Del Romero, Carmen Rodríguez, Teresa Puerta, Juan
Carlos Carrió, Mar Vera, Juan Ballesteros, Oskar Ayerdi.
Hospital Universitario Son Espases (Palma de Mallorca): Melchor Riera, María Peñaranda,
María Leyes, Mª Angels Ribas, Antoni A Campins, Carmen Vidal, Francisco Fanjul, Javier Murillas,
Francisco Homar.
Hospital Universitario Virgen de la Victoria (Málaga): Jesús Santos, Crisitina Gómez Ayerbe,
Isabel Viciana, Rosario Palacios, Carmen María González.
Hospital Universitario Virgen del Rocío (Sevilla): Pompeyo Viciana, Nuria Espinosa, Luis
Fernando López-Cortés.
Hospital Universitario de Bellvitge (Hospitalet de Llobregat): Daniel Podzamczer, Elena Ferrer,
Arkaitz Imaz, Juan Tiraboschi, Ana Silva, María Saumoy.
Hospital Costa del Sol (Marbella): Julián Olalla, Alfonso del Arco, Javier de la torre, José Luis
Prada, José María García de Lomas Guerrero, Javier Pérez Stachowski.
Hospital General Universitario Santa Lucía (Cartagena): Onofre Juan Martínez, Francisco Jesús
Vera, Lorena Martínez, Josefina García, Begoña Alcaraz, Amaya Jimeno.
Complejo Hospitalario Universitario a Coruña (Chuac) (A Coruña): Angeles Castro Iglesias, Berta
Pernas Souto, Alvaro Mena de Cea.
Hospital Universitario Virgen de la Arrixaca (El Palmar): Carlos Galera, Helena Albendin,
Aurora Pérez, Asunción Iborra, Antonio Moreno, Maria Angustias Merlos, Asunción Vidal.
Hospital Universitario Infanta Sofia (San Sebastian de los Reyes): Inés Suárez-García, Eduardo
Malmierca, Patricia González-Ruano, Dolores Martín Rodrigo, Mª Pilar Ruiz Seco.
Complejo Hospitalario de Jaén (Jaén) Mohamed Omar Mohamed-Balghata, María Amparo
Gómez Vidal.
Hospital Clínico San Carlos (Madrid): Vicente Estrada Pérez, Maria Jesus Téllez Molina, Jorge
Vergas García, Juncal Pérez-Somarriba Moreno.
Hospital Universitario Fundación Jiménez Díaz (Madrid): Miguel Górgolas., Alfonso Cabello.,
Beatriz Álvarez., Laura Prieto.
Hospital Universitario Príncipe de Asturias (Alcalá de Henares): José Sanz Moreno, Alberto
Arranz Caso, Cristina Hernández Gutiérrez, María Novella Mena.
Hospital Clínico Universitario de Valencia (València): María José Galindo Puerto, Ramón
Fernando Vilalta, Ana Ferrer Ribera.
Hospital Reina Sofía (Córdoba): Antonio Rivero Román, Maria Teresa Brieva Herrero, Antonio
Rivero Juárez, Pedro López López, Isabel Machuca Sánchez, José Peña Martínez.
Hospital Universitario Severo Ochoa (Leganés): Miguel Cervero Jiménez, Rafael Torres Perea,
Juan José Jusdado Ruiz-Capillas.
Nuestra Señora de Valme (Sevilla): Juan A Pineda.
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